ArticleInfection prevention in practice2026
Epidemiology, risk factors and outcomes of
Article in Infection prevention in practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aim: The aim of this study was to evaluate risk factors, ribotype distribution and treatment outcomes, relapse, recurrence and 30-day mortality, among CDI patients in a UK district general hospital. Methods: A retrospective cohort study included all adult and paediatric inpatient and outpatient cases diagnosed with CDI between April 2023 and August 2024. Demographic characteristics, risk factors, CDI onset type, treatment regimens, ribotypes, relapse, recurrence and 30-day all-cause mortality were extracted from electronic records and analysed descriptively. Results: In total, 124 CDI episodes were analysed: 45.2% hospital-onset healthcare-associated, 16.1% community-onset healthcare-associated, 33.0% community-onset community-associated and 5.6% community-onset indeterminate. First episodes accounted for 84.7%, with relapse in 12.9% and recurrence in 2.4%. Key risk factors included prolonged or multiple hospitalisations (74%), broad-spectrum antibiotic exposure (71%), proton pump inhibitor therapy (49%), gastrointestinal disease (31.4%) and malignancy (24%). Patients aged >75 years had the highest relapse/recurrence rate (63.2%). Relapse (9%) and recurrence (4%) occurred among those treated with oral vancomycin, whereas no relapse or recurrence was observed among patients who received fidaxomicin monotherapy. Ribotyping was completed in 108 cases (87.1%). Four ribotypes, CE002, CE005, CE015 and CE020, were most frequent (each Conclusions: Relapse and recurrence were more frequently observed among older patients and those with repeated hospitalisation, prior broad-spectrum antibiotic exposure, and gastrointestinal or malignant disease. No further episodes were observed among patients who received fidaxomicin monotherapy in this cohort. Ribotype patterns revealed predominance of non-hypervirulent strains, supporting strengthened stewardship and routine ribotype-informed surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.